Stifel Nicolaus Cuts Alto Neuroscience (NYSE:ANRO) Price Target to $10.00

Alto Neuroscience (NYSE:ANRO) had its price objective cut by Stifel Nicolaus from $32.00 to $10.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also issued reports on ANRO. RODMAN&RENSHAW lowered shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a report on Tuesday, September 10th. Wedbush lowered shares of Alto Neuroscience from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $29.00 to $4.00 in a report on Wednesday, October 23rd. Robert W. Baird cut their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday, October 23rd. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.00.

Alto Neuroscience Price Performance

Alto Neuroscience stock opened at $4.52 on Wednesday. Alto Neuroscience has a 52 week low of $3.61 and a 52 week high of $24.00. The company has a current ratio of 13.10, a quick ratio of 19.85 and a debt-to-equity ratio of 0.05. The firm’s 50-day simple moving average is $9.86 and its 200 day simple moving average is $11.41.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.05. On average, equities analysts predict that Alto Neuroscience will post -2.63 EPS for the current year.

Institutional Trading of Alto Neuroscience

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. acquired a new stake in Alto Neuroscience during the 1st quarter worth approximately $8,233,000. Price T Rowe Associates Inc. MD acquired a new stake in Alto Neuroscience during the 1st quarter worth approximately $9,788,000. Bowie Capital Management LLC acquired a new stake in Alto Neuroscience in the second quarter valued at approximately $462,000. TD Asset Management Inc acquired a new stake in Alto Neuroscience in the second quarter valued at approximately $928,000. Finally, Zimmer Partners LP acquired a new stake in Alto Neuroscience in the first quarter valued at approximately $1,151,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.